In a filing, Ocular Therapeutix Inc revealed its insider Dugel Pravin unloaded Company’s shares for reported $0.15 million on Feb 24 ’25. In the deal valued at $6.87 per share,21,475 shares were sold. As a result of this transaction, Dugel Pravin now holds 3,520,318 shares worth roughly $29.96 million.
Then, Heier Jeffrey S. sold 3,061 shares, generating $21,029 in total proceeds. Upon selling the shares at $6.87, the Chief Scientific Officer now owns 265,998 shares.
Before that, Kaiser Peter sold 3,009 shares. Ocular Therapeutix Inc shares valued at $20,672 were divested by the Chief Development Officer at a price of $6.87 per share. As a result of the transaction, Kaiser Peter now holds 210,078 shares, worth roughly $1.79 million.
Needham initiated its Ocular Therapeutix Inc [OCUL] rating to a Buy in a research note published on March 11, 2025; the price target was $15. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. TD Cowen also remained covering OCUL and has increased its forecast on June 20, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of OCUL
On Tuesday, Ocular Therapeutix Inc [NASDAQ:OCUL] saw its stock jump 11.24% to $8.51. Over the last five days, the stock has gained 30.92%. Ocular Therapeutix Inc shares have fallen nearly -0.35% since the year began. Nevertheless, the stocks have fallen -17.94% over the past one year. While a 52-week high of $11.77 was reached on 01/07/25, a 52-week low of $4.06 was recorded on 03/04/25. SMA at 50 days reached $7.75, while 200 days put it at $8.28.
Levels Of Support And Resistance For OCUL Stock
The 24-hour chart illustrates a support level at 7.97, which if violated will result in even more drops to 7.44. On the upside, there is a resistance level at 8.84. A further resistance level may holdings at 9.18. The Relative Strength Index (RSI) on the 14-day chart is 64.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.80, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 4.55%. Stochastics %K at 95.82% indicates the stock is a selling.
The most recent change occurred on February 09, 2024 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
